165806-41-7Relevant academic research and scientific papers
Isonitrile intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties
-
Page 23, (2010/01/31)
The invention relates to a novel group of isonitrile compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.
Imine intermediates for the preparation of trisubstituted imidazole compounds with multiple therapeutic properties
-
Page 24, (2010/01/31)
The invention relates to a novel group of iminc compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.
Formamide intermediates for the preparation of tri-substituted imidazole compounds with multiple therapeutic properties
-
Page 24, (2010/02/05)
The invention relates to a novel group of formamide compounds and a process for their preparation, useful in the preparation of tri-substituted imadazoles having multiple therapeutic properties.
Treatment for CNS injuries
-
, (2008/06/13)
Use of 1,4,5-substituted imidazole compounds and compositions in the treatment of CNS injuries to the brain.
Imidazole compounds, use and process of making
-
, (2008/06/13)
Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.
Pyridyl imidazole compounds and compositions
-
, (2008/06/13)
Novel 1, 4, 5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.
1-Substituted 4-aryl-5-pyridinylimidazoles: A new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency
Boehm, Jeffrey C.,Smietana, Juanita M.,Sorenson, Margaret E.,Garigipati, Ravi S.,Gallagher, Timothy F.,Sheldrake, Peter L.,Bradbeer, Jeremy,Badger, Alison M.,Laydon, Jeffrey T.,Lee, John C.,Hillegass, Leonard M.,Griswold, Donald E.,Breton, John J.,Chabot-Fletcher, Marie C.,Adams, Jerry L.
, p. 3929 - 3937 (2007/10/03)
A series of 1-alkyl- or -aryl-4-aryl-5-pyridinylimidazoles (A) were prepared and tested for their ability to bind to a recently discovered protein kinase termed CSBP and to inhibit lipopolysaccharide (LPS)-stimulated TNF production in mice. The kinase, CS
